PFS Partners’s aTyr Pharma ATYR Stock Holding History

PFS Partners’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-340	Closed	-$1.03K	–	521
2025 Q1	$1.03K	Hold	340	–	–	﹤0.01%	409
2024 Q4	$1.23K	Hold	340	–	–	﹤0.01%	412
2024 Q3	$599	Hold	340	–	–	﹤0.01%	424
2024 Q2	$531	Hold	340	–	–	﹤0.01%	414
2024 Q1	$663	Hold	340	–	–	﹤0.01%	433
2023 Q4	$480	Sell	340 -60	-15%	-$77	﹤0.01%	433
2023 Q3	$632	Hold	400	–	–	﹤0.01%	436
2023 Q2	$864	Sell	400 -6	-1%	-$13	﹤0.01%	448
2023 Q1	$853	Hold	406	–	–	﹤0.01%	361
2022 Q4	$890	Hold	406	–	–	﹤0.01%	348
2022 Q3	$1.22K	Hold	406	–	–	﹤0.01%	333
2022 Q2	$1.15K	Hold	406	–	–	﹤0.01%	329
2022 Q1	$2.17K	Hold	406	–	–	﹤0.01%	307
2021 Q4	$3.03K	Buy	+406	New	+$3.39K	﹤0.01%	289

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PFS Partners's ATYR Position: Q2 2025 in Review

PFS Partners sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 340 shares — an estimated $1.03K sold.

PFS Partners first reported a position in ATYR in Q4 2021 and held it in 14 quarters. The position peaked at $3.03K in Q4 2021. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

PFS Partners reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
PFS Partners sold 340 aTyr Pharma shares in Q2 2025, an estimated $1.03K.
PFS Partners first reported a position in aTyr Pharma in Q4 2021 and held it in 14 quarters.
PFS Partners's aTyr Pharma position peaked at $3.03K in Q4 2021.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on PFS Partners's 13F filing for Q2 2025, filed 16 Jul 2025.